Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $11,761.92 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 18,378 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $0.64, for a total value of $11,761.92. Following the completion of the transaction, the director owned 2,453,919 shares in the company, valued at $1,570,508.16. The trade was a 0.74% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Luke Evnin also recently made the following trade(s):

• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total transaction of $26,494.65.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.62, for a total transaction of $15,476.44.
• On Tuesday, December 30th, Luke Evnin sold 34,847 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total transaction of $21,256.67.
• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total transaction of $66,249.66.
• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $22,448.16.
• On Wednesday, December 24th, Luke Evnin sold 16,310 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.65, for a total value of $10,601.50.
• On Tuesday, December 23rd, Luke Evnin sold 71,428 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $44,999.64.
• On Monday, December 22nd, Luke Evnin sold 59,307 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total value of $40,921.83.

Werewolf Therapeutics Stock Performance

NASDAQ HOWL opened at $0.60 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. The stock’s fifty day moving average is $0.89 and its two-hundred day moving average is $1.25. The firm has a market capitalization of $29.29 million, a P/E ratio of -0.37 and a beta of 0.77. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.56 and a fifty-two week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on HOWL. Citizens Jmp downgraded shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, December 19th. Citigroup lowered shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, December 19th. Wedbush cut Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price objective on the stock. in a report on Friday, December 19th. Bank of America cut their target price on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Finally, Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. Three investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Werewolf Therapeutics has a consensus rating of “Hold” and a consensus price target of $3.75.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in HOWL. Jane Street Group LLC purchased a new position in shares of Werewolf Therapeutics during the second quarter worth $409,000. Citadel Advisors LLC purchased a new stake in shares of Werewolf Therapeutics in the 3rd quarter valued at $304,000. Vanguard Group Inc. raised its holdings in shares of Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after buying an additional 109,796 shares during the period. Marshall Wace LLP acquired a new position in Werewolf Therapeutics during the 2nd quarter worth about $113,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Werewolf Therapeutics during the 2nd quarter valued at about $92,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.